Tiernan Meyer

Tiernan Meyer supports Avalere clients in analytic and strategic engagements focused on Medicaid, state health policy trends, and the impact of federal health reform.

Tiernan leads Avalere’s Medicaid policy tracking, including states’ decisions around expanding Medicaid under the Affordable Care Act and our analysis of trends and enrollment in Medicaid managed care. She follows Medicaid trends with a particular focus on pharmaceuticals and state cost containment and has expertise in private exchanges and benefit design trends.

Prior to joining Avalere, Tiernan worked as a health educator at the Delta Area Health Education Center in Helena, AR. Additionally, she analyzed the Chilean public healthcare system while studying in Concepción, Chile.

Tiernan has a BA in neuroscience from Middlebury College.

Authored Content

Avalere analysis finds that tying Medicare Part D manufacturer discounts to utilization in the catastrophic phase instead of in the coverage gap would have differential impacts by disease area.

Avalere analysis finds that a larger proportion of beneficiaries taking a Part D cancer therapy reached catastrophic compared to all Part D enrollees.

New research from Avalere finds that capped funding policies could reduce federal funding to states, specifically for children, by $89B to $163B nationally for FY 2020–2029.

As policymakers increasingly consider policy options to reform Medicare Part D and reduce program expenditures, an Avalere analysis examines spending across classes with various availability of brand and generic drugs.

On April 5, CMS issued guidance announcing a voluntary, 2-year demonstration that would modify the Part D risk corridors if the proposed rule to revise the Anti-Kickback Statute safe harbors is effective for 2020.

Tune in for episode 2 of our mid-term elections podcast. Avalere experts, Chris Sloan and Tiernan Meyer, discuss potential state and federal-level scenarios for Medicaid expansion.

Reforms to “eliminate rebates” could have varying impacts based on features of their design.

On June 27, CMS notified Massachusetts of a partial approval of the MassHealth program’s proposed 1115 waiver request.

On March 6, Avalere experts came together to discuss the latest Medicaid developments.

Avalere experts discuss an evolving Medicaid program supported by a new administration and novel state approaches.

Beneficiaries show signs of pent-up demand with acute healthcare needs early in their enrollment, but over time costs increase substantially and shift toward chronic care.

New analysis from Avalere finds that the Graham-Cassidy-Heller-Johnson (GCHJ) bill to repeal and replace the Affordable Care Act (ACA) would lead to a substantial reduction in federal Medicaid funding to states of $713B through 2026 and more than $3.5T over a 20-year period if block grant funding is not reauthorized (Figure 1).

The Better Care Reconciliation Act (BCRA) would cap Medicaid funding to states. In this analysis, Avalere worked with The SCAN Foundation to examine how BCRA Medicaid changes would impact dual-eligible beneficiaries. We compare these outcomes to the impact of the House-approved American Health Care Act.

New analysis from Avalere finds that states could see federal funding for their Medicaid programs decline by between 6% and 26% under the Better Care Reconciliation Act (BCRA) by 2026.

Across 8 therapeutic areas, the Veteran's Administration (VA) National Formulary covers 49 percent fewer drugs than Ohio's largest Medicaid managed care plan and 68 percent fewer drugs than the Ohio Medicaid preferred drug list (PDL).

Capping Medicaid funding could also shift costs to Medicare

Analysis shows Medicaid block grants and per capita caps could result in state budget gaps.

While 31 states and DC expanded Medicaid under the ACA, the future of expansion is uncertain.

New analysis from Avalere finds that 1.2 million individuals from non-expansion states could gain Medicaid coverage in 2017 should a newly elected governor decide to expand the program.